What we're about
Upcoming events (5)
Join local pet care startups and national industry leaders for an evening of exploring what's going on in the Bay Area and how the startups here can grow with investment and corporate relationships. The pet care industry is a $75B industry in just the United States, and startups are making a major impact. The Pet Care Innovation Prize is a program that gives cash and valuable business support to up to five innovative pet care companies per year - without the startups giving up any rights or equity. Light snacks and beverages will be served. Active Capital and 9-Square Ventures present the Pet Care Innovation Prize, powered by Purina.
To attend this event, please RSVP on Eventbrite: https://www.eventbrite.com/e/design-jam-accelerating-science-through-technology-tickets-61662506216 Join us in Downtown Berkeley for a Design Jam: Accelerating Science Through Technology. What is a Design Jam? A Design Jam is a mini-hackathon where a challenge/prompt is presented in the beginning of the event. The challenge will be related to solving problems related to the advancement of science. Attendees will be getting in groups of 5-6 and will have one hour to come up with an innovative solution to this problem. Accelerating Science Through Technology With the digital information age, we are given many opportunities to access information. Scientific and technology advances in communication and the way we share knowledge is growing fast. This event will allow attendees to focus on these shifts in industry. This event will be hosting designers, scientists, and anyone interested in science and technology. No prior experience required, all are welcome! To attend this event, please RSVP on Eventbrite: https://www.eventbrite.com/e/design-jam-accelerating-science-through-technology-tickets-61662506216
*** RSVP on Eventbrite: https://www.eventbrite.com/e/future-of-therapeutics-diagnostics-tickets-61910409702 *** Cancer, antibiotic-resistant infections, immune disorders, microbiome disorders, and aging are looming health treats to everyone. How can we use biotech and computation to outsmart these diseases? Come hear from five startups that are working on the next generation of therapeutics and diagnostics. Light snacks and drinks served. Speakers: Helen Chen, CEO of Guided Clarity (gclarity.com) Guided Clarity has developed a new class of compounds to target and clear cells of dysfunctional mitochondria, improving cellular energy production. Their compounds are synthesized from naturally-occurring ingredients in food, so they are both safe and affordable as a medical food. In their first clinical study on healthy volunteers, the data showed an increase in insulin sensitivity, a reduction in inflammation marker NLR, and improved physical function. Guided Clarity is focused on healthy aging, improving mitochondrial function both in the brain and on the periphery. Michael Wyman, CEO of Beeline Therapeutics (beelinetherapeutics.com) Beeline turns your body’s own cells into drug factories to express antibodies, enzymes, or cytokines. Their method facilitates localized drug expression. They replace expensive therapeutic protein regimens that have to be injected weekly or monthly. They’re working to reprogram a patient’s immune cells to suppress inflammation and autoimmune disease, effectively curing patients for many years. Kevin Honaker, CEO of BiomeSense (biomesenseinc.com) The microbiome is one of the most impactful emerging fields in healthcare, yet fundamentally constrained by a lack of biomarkers to measure treatment efficacy. BiomeSense’s platform is a 30x reduction in the cost of doing longitudinal microbiome collection and analysis research, unlocking this exploding market. Their single-chip, on-toilet design will prep and assay the microbiome strains and upload the data to their cloud. BiomeSense is quickly signing pilot partners to use their device in clinical trials, as well as securing LOIs with partners who desire access to their unique, centralized data. Franco Goytia, CEO of Caspr Bio (http://caspr.bio) Caspr is a diagnostics company that uses CRISPR for rapid detection of antimicrobial resistance. Today, when a patient has an infection, it takes three days to determine which bacterial strains are proliferating. Physicians are desperate to know, faster, if a patient has the resistant superbug KPC, or bacteria with the resistant-gene NDM-1. Caspr Bio is making an affordable, point-of-care device that can make this diagnosis in two hours. They use CRISPR to identify the DNA of the most dangerous infectious strains. They will be extending this platform to upgrade many diagnostics with CRISPR. Marcel Frenkel, Co-founder of Gavilan Biodesign (gavilanbio.com) Gavilan Biodesign is an in silico computational design company that redesigns drugs for pharma companies, so cancers cannot develop resistance to the drug. Cancer cells mutate rapidly and comes back after most therapeutic treatments. Currently, pharma companies design drugs to target a specific, likely mutation. But then a new mutation makes the cancer resistant to that drug, too. Gavilan is a unique computational drug design company with capabilities new to this field. Their physics-based engine models all possible mutations around a binding site to predict which set of mutations will successfully emerge. Then they redesign a drug to remain effective, not just against one or two mutations, but against all possible future mutations. They can search through 100 trillion molecular structures a day, arriving at superior drug compound structures in a matter of hours. Their goal is to work with many pharma partners to create a new class of targeted therapies that dramatically extend progression-free survival.
*** RSVP on Eventbrite: https://www.eventbrite.com/e/medgenome-immune-profiling-applications-symposium-tickets-61940796590 *** Please join us for an exciting line of speakers for MedGenome's June 4th symposium on Genomics & Immune profiling applications. Dinner will be served at the event. Speaker : Sarah Taylor, PhD, Staff Scientist, 10x Genomics Title : High Resolution Profiling of the Antigen-Specific T Cell Response Speaker : Mark White, PhD, Sr. Director, Scientific Affairs at Berkeley Lights, Inc. Title: Stuck on function? Analyze the function of individual T cells in 1 day Speaker : Rikhia Chakraborty, PhD, Assistant Professor, Texas Childrens' Hospital Title : Terrible T’s in LCH Sampathkumar Rangasamy, PhD Assistant Professor, TGEN Title : Importance of disease phenotype in rare and complex disorders